Taiwan Liposome Gets the Go-Ahead for a Hydroxychloroquine COVID-19 Study

By Chris Lange Published Oct 7, 11:32AM EDT

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Taiwan Liposome Gets the Go-Ahead for a Hydroxychloroquine COVID-19 Study — © Paula Bronstein / Getty Images News via Getty Images

Taiwan Liposome Co. Ltd. (NASDAQ: TLC) shares shot up on Wednesday after the firm announced that it would be able to move forward with its COVID-19 trial that uses hydroxychloroquine. In the past, hydroxychloroquine has been viewed as a controversial drug in terms of evaluating its efficacy in treating COVID-19, but now there seems to be a definitive ruling on it—at least in Australia and Taiwan.

In terms of the specifics, the company announced the receipt of ethical and scientific approval from the Bellberry Human Research Ethics Committee (HREC) in Australia for the company’s Phase 1 clinical trial of TLC19 hydroxychloroquine liposome inhalation suspension for COVID-19.

The HREC is constituted in accordance with the requirements of the National Health & Medical Research Council (NHMRC), and it reviews clinical trial proposals to ensure that they are ethically and scientifically acceptable and have been developed in accordance with relevant standards and guidelines.

The approval comes following the acceptance of Taiwan Liposome’s investigational new drug (IND) application with the Taiwan Food and Drug Administration (TFDA) on Tuesday.

[nativounit]

Ultimately, the Phase 1 study will evaluate the safety, tolerability and pharmacokinetics of single ascending doses of inhaled TLC19 in 30 healthy volunteers.

Management said that it is very much looking forward to launching TLC19’s Phase 1 trial with the support of experienced, high-quality partners in Taiwan as well as in Australia, which has an efficient and globally recognized regulatory environment with the bonus of government incentives and benefits and is a great place to conduct clinical trials for time-sensitive projects like TLC19.

Excluding Wednesday’s move, Taiwan Liposome stock had underperformed the broad markets with a retreat of about 18% year to date. In the past 52 weeks, the share price was down closer to 13%.

Taiwan Liposome stock traded up about 42% to $6.17 on Wednesday, in a 52-week range of $2.48 to $12.65. The consensus price target is $12.75.

[recirclink id=800455][wallst_email_signup]

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.